This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vera-Cabrera, L.
Right arrow Articles by Molina-Torres, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vera-Cabrera, L.
Right arrow Articles by Molina-Torres, C. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2006, p. 4027-4029, Vol. 50, No. 12
0066-4804/06/$08.00+0     doi:10.1128/AAC.00763-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

In Vitro Activities of the Novel Oxazolidinones DA-7867 and DA-7157 against Rapidly and Slowly Growing Mycobacteria{triangledown}

Lucio Vera-Cabrera,1* Barbara A. Brown-Elliott,2 Richard J. Wallace Jr.,2 Jorge Ocampo-Candiani,1 Oliverio Welsh,1 Sung Hak Choi,3 and Carmen A. Molina-Torres1

Servicio de Dermatología, Hospital Universitario José E. González, Monterrey, N.L., México,1 Department of Microbiology, The University of Texas Health Center, Tyler, Texas,2 Research Laboratory, Dong-A Pharmaceutical Co., Ltd., Yongin, Korea3

Received 22 June 2006/ Returned for modification 7 August 2006/ Accepted 20 September 2006

DA-7867 and DA-7157 are oxazolidinones active against pathogenic aerobic actinomycetes including Nocardia spp. and Mycobacterium tuberculosis. However, the activity of these drugs against nontuberculous mycobacterium (NTM) species is not known. In this work, we compared the susceptibilities of 122 clinical isolates and 29 reference species of both rapidly growing and slowly growing mycobacteria to linezolid, DA-7867, and DA-7157 by the broth microdilution method. The MICs for 50 and 90% of the strains tested (MIC50s and MIC90s, respectively) of DA-7867 and DA-7157 were lower than those of linezolid. In all of the cases, a MIC90 of <8 µg/ml was observed for all of the species tested in both groups of NTM. For M. kansasii and M. marinum isolates, the MIC90s of both DA-7867 and DA-7157 were less than 0.5 µg/ml. These results demonstrate the potential of these compounds to treat NTM infections.

* Corresponding author. Mailing address: Servicio de Dermatología, Hospital Universitario José E. González, Madero y Gonzalitos, Col. Mitras Centro, Monterrey, N.L., México. Phone: 011(5283) 8348-0383. Fax: 011(5283) 8348-4407. E-mail: luvera_99{at}yahoo.com.

{triangledown} Published ahead of print on 2 October 2006.

Antimicrobial Agents and Chemotherapy, December 2006, p. 4027-4029, Vol. 50, No. 12
0066-4804/06/$08.00+0     doi:10.1128/AAC.00763-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»